Please use this identifier to cite or link to this item: https://ah.nccu.edu.tw/handle/140.119/79418


Title: Early treatment response predicted subsequent clinical response in patients with schizophrenia taking paliperidone extended-release
Authors: Yeh, En-Chi;Huang, Ming-Chyi;Tsai, Chang-Jer;Chen, Chun-Tse;Chen, Kuan-Yu;Chiu, Chih-Chiang
蔡長哲
Contributors: 神科所
Keywords: Antipsychotic;Dosing;Pharmacokinetics;Responder
Date: 2015-11
Issue Date: 2015-11-25 16:35:42 (UTC+8)
Abstract: This 6-week open-labeled study investigated whether early treatment response in patients receiving paliperidone extended-release (paliperidone ER) can facilitate prediction of responses at Week 6. Patients with schizophrenia or schizoaffective disorder were administered 9 mg/day of paliperidone ER during the first 2 weeks, after which the dose was adjusted clinically. They were assessed on Days 0, 4, 7, 14, 28, and 42 by the Positive and Negative Syndrome Scale (PANSS). The serum concentrations of 9-hydroxyrisperidone were examined on Days 14 and 42. Among the 41 patients enrolled, 26 were classified as responders (≧50% improvement on total PANSS scores at Week 6). In the receiver-operator curves (ROC) analyses, the changes in total PANSS scores at Week 2 appeared to show more accurate predictability compared to Day 4 and Day 7. At Week 6, no significant correlation was observed between blood 9-hydroxyrisperidone concentration and the total score or changes of PANSS scores. The results suggest that early treatment response to paliperidone ER, particularly at Week 2, can serve as a suitable outcome predictor at Week 6. Using 9 mg/day paliperidone ER as an initial dose for schizophrenia treatment exhibited relatively favorable tolerability and feasibility.
Relation: Psychiatry Research, 230(1), 13-18
Data Type: article
DOI 連結: http://dx.doi.org/10.1016/j.psychres.2015.07.037
Appears in Collections:[應用物理研究所 ] 期刊論文

Files in This Item:

File Description SizeFormat
13-18.pdf428KbAdobe PDF494View/Open


All items in 學術集成 are protected by copyright, with all rights reserved.


社群 sharing